Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD. View Limitations of Use.
See the efficacy data from the Ozempic® clinical trial program
aResults apply to Ozempic® plus standard of care vs standard of care alone in SUSTAIN 6 trial.
MACE=CV death, nonfatal myocardial infarction, or nonfatal stroke
What could your patients who make the change to Ozempic® expect?
bData from VANTAGE Fingertip Formulary bridge/July 2020 Nomenclature, and Xponent PlanTrak using week ending 08/02/2019; only considers bridged volume; excludes cash and mail order data; based on full DCS/EDCS/IDCS/HSDCS IC universe targets and non-targets).
cEligible commercially insured patients with coverage for Ozempic® pay as little as $25 for a 1-month or 3-month supply with the Ozempic® savings offer. Month is defined as 28 days. Maximum savings is $150 for 1-month or $450 for 3-month supply. Offer is good for up to 24 months. Eligibility and restrictions apply.